Surrozen reports developments as a clinical-stage biotechnology company developing Wnt-based targeted therapeutics for sight-threatening ophthalmic diseases. Company updates center on its ophthalmology pipeline, including SZN-8141 and SZN-8143 in retinal diseases, antibody-engineering work, financial results, collaboration and license revenue, and research milestones tied to Boehringer Ingelheim.
Recurring announcements also cover healthcare investor conference presentations, Nasdaq inducement equity grants under the 2025 Equity Inducement Plan, and corporate governance or leadership matters that affect the company's public-company reporting profile.
Surrozen (SRZN) received FDA clearance of its investigational new drug application for SZN-8141, enabling clinical development for diabetic macular edema.
The company expects to dose the first patient in DUET, a Phase 1b/2a study in patients with diabetic macular edema, in the fourth quarter of 2026. The clearance also satisfies the milestone for the second closing of its March 2025 two-tranche private placement.
Surrozen expects that closing on or about October 20, 2026, subject to applicable closing conditions, to provide approximately $95.1 million in gross proceeds before placement agent fees and other expenses. The securities include common shares, pre-funded warrants and Series E common stock warrants.
Surrozen (SRZN) has submitted an Investigational New Drug (IND) application to the U.S. FDA to evaluate SZN-8141 for the treatment of diabetic macular edema (DME).
SZN-8141 is described as a bifunctional antibody that both activates the Wnt pathway and antagonizes VEGF, aiming to reduce vascular leakage and support retinal vascular integrity in a single molecule. In preclinical rodent models of retinal vascular disease, SZN-8141 showed superior reductions in neovascularization and improved retinal revascularization versus Wnt agonist or anti-VEGF monotherapy, and greater reductions in vascular leakage than anti-VEGF therapy in a neovascular age-related macular degeneration model. The candidate will be tested in DUET, a Phase 1b/2a trial in DME patients designed to assess safety, tolerability, and early biological and clinical activity, which Surrozen expects to start by year-end 2026, with initial data anticipated in the second half of 2027.
Surrozen (SRZN) will present at two upcoming healthcare investor conferences in September 2026. Management will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on September 10 at 6:10 AM Pacific / 9:10 AM Eastern. A second fireside chat is scheduled at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16 at 10:50 AM Pacific / 1:50 PM Eastern. Live audio webcasts and replays will be available through the Investors section of Surrozen’s website for at least 30 days.
Surrozen (Nasdaq: SRZN) reported second quarter 2026 results and a business update. The company plans to submit an IND for SZN-8141 in diabetic macular edema by the end of Q3 2026 and to initiate the DUET Phase 1b/2a trial by year-end 2026, with initial data expected in the second half of 2027.
In June 2026, Boehringer Ingelheim triggered a development milestone under the SZN-413 license following Phase 1 initiation. In July 2026, the U.S. PTAB denied institution of Merck’s post-grant review petition against certain claims of Surrozen’s U.S. Patent No. 12,297,278. Q2 2026 revenue was $5.0 million, entirely from collaboration and license revenue, versus $1.0 million total revenue a year earlier. R&D expenses rose to $8.5 million and G&A to $6.9 million, driving a $10.4 million operating loss.
Non-cash gains on tranche and warrant liabilities contributed to net income of $50.2 million for Q2 2026, compared to $39.7 million in Q2 2025. Cash and cash equivalents were $102.0 million as of June 30, 2026. For the first six months of 2026, Surrozen recorded a net loss of $77.3 million and reported a stockholders’ deficit of $218.7 million.
Surrozen (Nasdaq: SRZN) announced that management will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, featuring a fireside chat at 10:00 AM Pacific / 1:00 PM Eastern.
The audio webcast will be available via the Investors section of Surrozen’s website beginning at 1:00 PM Eastern on July 22, 2026, with a replay accessible for at least 30 days.
Surrozen (Nasdaq: SRZN) announced that company management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026. The presentation will be a fireside chat at 11:30 AM Eastern Time / 8:30 AM Pacific Time.
A live audio webcast will be available via the Investors section of Surrozen’s website, with a replay archived on surrozen.com for at least 30 days.
Surrozen (Nasdaq: SRZN) reported Q1 2026 results and a business update. The company had $106.9 million in cash and cash equivalents as of March 31, 2026, and recognized $5.0 million collaboration revenue from a Boehringer Ingelheim milestone. Surrozen remains on track to submit an IND for SZN-8141 in H2 2026. R&D expenses were $9.3 million and G&A expenses were $6.1 million for the quarter. Net loss was $127.5 million or $11.65 per share, driven largely by non-cash changes in fair value of tranche and warrant liabilities.
Surrozen (Nasdaq: SRZN) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) dated April 24, 2026. The company granted a non-statutory stock option for 2,020 shares to a newly hired non-executive employee under the 2025 Equity Inducement Plan.
The option exercise price is $28.14 per share (Nasdaq closing price on April 24, 2026). The option vests over four years: 25% at the one-year anniversary and the remainder ratably each month over 36 months, subject to continued service.
Surrozen (Nasdaq: SRZN) reported fourth-quarter and full-year 2025 results and a business update on March 23, 2026. Key items: planned IND submission for SZN-8141 in H2 2026, a $5.0M milestone payment from Boehringer Ingelheim for SZN-413, and presentations at ARVO 2026.
Financials: cash and cash equivalents $89.2M as of Dec 31, 2025; FY2025 net loss $242.0M ($32.37/share); R&D expenses $29.4M; continued pipeline and leadership hires to support ophthalmology strategy.
Surrozen (Nasdaq: SRZN) will present at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026 with a fireside chat at 1:10 PM ET / 10:10 AM PT. Interested parties can listen via a live audio webcast.
A replay will be archived on the company website for at least 30 days following the event.